Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.